HDAC6-IN-13(Compound 35m)是一种强效、高选择性且具有口服活性的 HDAC6 抑制剂,IC50 为 0.019 μM,同时也可抑制 HDAC1、HDAC2 和 HDAC3,IC50 分别为 1.53、2.06 和 1.03 μM,并具有明显的血脑屏障通透性和抗炎活性。
产品编号: MS-X17244 纯度: 98.08% CAS No.: 2837128-41-1 分子式: C23H22N4O 分子量: 370.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

HDAC6-IN-13(Compound 35m)是一种强效、高选择性且具有口服活性的 HDAC6 抑制剂,IC50 为 0.019 μM,同时也可抑制 HDAC1、HDAC2 和 HDAC3,IC50 分别为 1.53、2.06 和 1.03 μM,并具有明显的血脑屏障通透性和抗炎活性。

生物实验数据

生物活性 HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active HDAC6 inhibitor with an IC50 of 0.019 μM, which also inhibits HDAC1, HDAC2, and HDAC3 with IC50 values of 1.53, 2.06, and 1.03 μM, respectively, and exhibits significant blood-brain barrier permeability and anti-inflammatory activity.
IC50 & Target

HDAC6

0.019 μM (IC50)

HDAC3

1.03 μM (IC50)

HDAC1

1.53 μM (IC50)

HDAC2

2.06 μM (IC50)

体外研究
(In Vitro)

HDAC6-IN-13 (Compound 35m) (0.1-1 μM; 24 h) is highly selective toward HDAC6 versus class I HDACs.
HDAC6-IN-13 is a slow-on and slow-off tight-binding HDAC6 inhibitor, while exhibits fast-on properties for HDAC1, 2, and 3.
HDAC6-IN-13 (5-20 μM; 8 h) shows anti-inflammatory activity in vitro.

Western Blot Analysis

Cell Line: MV4−11 and J774A.1
Concentration: 0.1, 0.2, 0.5 and 1 μM
Incubation Time: 24 h
Result: Concentration-related accumulation of acetylated tubulin (Ac-Tubulin) was observed, while upregulation of acetylated histone H3 (AcHH3) and acetylated histone H4 (AcHH4) was not apparent even at the concentration of 1 μM.

Western Blot Analysis

Cell Line: J774A.1 cells
Concentration: 5, 10 and 20 μM
Incubation Time: 8 h
Result: Inhibited the cleavage of pro-caspase 1 to p20 in a dose-dependent manner, inhibited the interaction between HDAC6 and dynein.
体内研究
(In Vivo)

HDAC6-IN-13 (Compound 35m) (20 mg/kg; p.o. and i.p.; once) displays a remarkable inhibition in LPS-induced inflammation in mice.
HDAC6-IN-13 (20 mg/kg; p.o.; once) shows very high oral bioavailability (F% = 93.4%) and significant BBB permeability in mice.

Animal Model: Male C57BL/6 WT mice, LPS-induced endotoxic shock model
Dosage: 20 mg/kg
Administration: PO and IP, immediately after the LPS injection
Result: Significantly decreased the serum IL-1β levels in LPS-induced mice via both ip and po administration.
Animal Model: Male CD-1 mice
Dosage: 5 mg/kg or 20 mg/kg
Administration: IV (5 mg/kg) or PO (20 mg/kg) (Pharmacokinetic Study)
Result: Pharmacokinetics Characterization of HDAC6-IN-13 (Compound 35m) with iv and Oral Administrationa
PK parameters HDAC6-IN-13 HDAC6-IN-13
administered dose (mg/kg) iv at 5 mg/kg oral at 20 mg/kg
Cmax (ng/mL) 4604 ± 551 5570 ± 551
t1/2 (h) 7.95 ± 0.370 6.80 ± 0.145
AUC0−inf (ng•h/mL) 2755 ± 395 10292 ± 1385
F% n/a 93.4 ± 12.6

aHDAC6-IN-13 was administrated via iv and po (n = 3). The blood sample was collected at different time points after dosing, and the plasma concentration of HDAC6-IN-13 was determined via LC-MS/MS. The area under the plasma concentration versus time curve (AUC) was calculated using the linear trapezoidal method. The pharmacokinetic parameters were obtained using the noncompartmental method. Data are shown as mean ± SD.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 370.45
分子式 C23H22N4O
CAS No. 2837128-41-1

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 125 mg/mL (337.43 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.6994 mL13.4971 mL26.9942 mL67.4855 mL
5 mM0.5399 mL2.6994 mL5.3988 mL13.4971 mL
10 mM0.2699 mL1.3497 mL2.6994 mL6.7485 mL
15 mM0.1800 mL0.8998 mL1.7996 mL4.4990 mL
20 mM0.1350 mL0.6749 mL1.3497 mL3.3743 mL
25 mM0.1080 mL0.5399 mL1.0798 mL2.6994 mL
30 mM0.0900 mL0.4499 mL0.8998 mL2.2495 mL
40 mM0.0675 mL0.3374 mL0.6749 mL1.6871 mL
50 mM0.0540 mL0.2699 mL0.5399 mL1.3497 mL
60 mM0.0450 mL0.2250 mL0.4499 mL1.1248 mL
80 mM0.0337 mL0.1687 mL0.3374 mL0.8436 mL
100 mM0.0270 mL0.1350 mL0.2699 mL0.6749 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础